Trial intelligence / Profile preview

ACT-ALONE: Glucocorticoid Reduction in RA Patients Treated With Tocilizumab

NCT01219933Phase 4Completed

Sponsor
Roche
Start
Jan 2011
Primary completion
Mar 2013
Modality
Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
Countries
1
01

Overview

A Phase 4 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Started Jan 2011; status: completed.

02

Drugs

tocilizumab
03

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on NCT01219933.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01219933.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call